» Articles » PMID: 34407421

Post-SARS-CoV-2 Vaccination Specific Antibody Decrease - Thresholds for Determining Seroprevalence and Seroneutralization Differ

Overview
Journal J Infect
Date 2021 Aug 18
PMID 34407421
Citations 10
Authors
Affiliations
Soon will be listed here.
Citing Articles

Evaluation of neutralizing antibody titers against SARS-CoV-2 JN.1 omicron subvariant during pregnancy - A case series study.

Didembourg M, David C, Morimont L, Cransquint E, Favresse J, Douxfils J Heliyon. 2025; 11(1):e41249.

PMID: 39811280 PMC: 11729664. DOI: 10.1016/j.heliyon.2024.e41249.


Vaccine-induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?.

Favresse J, Tre-Hardy M, Gillot C, Cupaiolo R, Wilmet A, Beukinga I Heliyon. 2024; 10(16):e36116.

PMID: 39247272 PMC: 11379571. DOI: 10.1016/j.heliyon.2024.e36116.


Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population.

Gillot C, Bayart J, Maloteau V, Dogne J, Douxfils J, Favresse J Case Rep Infect Dis. 2024; 2024:9163490.

PMID: 39246664 PMC: 11380708. DOI: 10.1155/2024/9163490.


SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization.

Souiri A, Lemriss S, El Maliki B, Falahi H, El Fahime E, El Kabbaj S Vaccines (Basel). 2023; 11(3).

PMID: 36992173 PMC: 10054367. DOI: 10.3390/vaccines11030590.


Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans.

Gdoura M, Ghaloum F, Hamida M, Chamsa W, Triki H, Bahloul C Sci Rep. 2022; 12(1):11298.

PMID: 35788676 PMC: 9252535. DOI: 10.1038/s41598-022-15378-1.